Predictions
Aptevo Therapeutics Inc.
Start price
Target price
Perf. (%)
€42.00
19.11.20
19.11.20
€50.00
19.11.21
19.11.21
-67.07%
07.11.21
07.11.21
Could be very worthwhile Investment >20% year
Pfizer Inc.
Start price
Target price
Perf. (%)
€31.40
18.11.20
18.11.20
-
18.11.21
18.11.21
45.06%
19.11.21
19.11.21
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Low dividend yield expected
Evoke Pharma Inc.
Start price
Target price
Perf. (%)
€32.66
18.11.20
18.11.20
€60.00
18.11.21
18.11.21
-3.60%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Seelos Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.66
18.11.20
18.11.20
€1.00
18.11.21
18.11.21
25.80%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Arca Biopharma
Start price
Target price
Perf. (%)
€3.36
18.11.20
18.11.20
€5.00
18.11.21
18.11.21
5.36%
30.11.20
30.11.20
Could be very worthwhile Investment >20% year
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€2.39
18.11.20
18.11.20
€4.00
30.50%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
MagForce AG
Start price
Target price
Perf. (%)
€3.01
18.11.20
18.11.20
€4.00
18.11.21
18.11.21
12.29%
19.11.21
19.11.21
Could be worthwhile Investment >10% per year
Neptune Wellness Solutions Inc
Start price
Target price
Perf. (%)
€60.55
16.11.20
16.11.20
€105.00
16.11.21
16.11.21
-10.40%
28.11.20
28.11.20
Could be worthwhile Investment >10% per year
Good rating
Differentiated customer and product portfolio
Risky balance sheet
Aptevo Therapeutics Inc.
Start price
Target price
Perf. (%)
€35.20
16.11.20
16.11.20
-
16.11.21
16.11.21
-77.34%
17.11.21
17.11.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Alterity Therapeutics Ltd. ADR
Start price
Target price
Perf. (%)
€25.50
16.11.20
16.11.20
-
16.11.21
16.11.21
-60.78%
17.11.21
17.11.21
Probably not worthwhile Investment
Innate Pharma
Start price
Target price
Perf. (%)
€4.10
15.11.20
15.11.20
€5.50
15.11.21
15.11.21
7.86%
16.11.21
16.11.21
Could be worthwhile Investment >10% per year
Aphria Inc.
Start price
Target price
Perf. (%)
€4.90
14.11.20
14.11.20
-
14.11.21
14.11.21
23.24%
27.11.20
27.11.20
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.30
14.11.20
14.11.20
-
14.11.21
14.11.21
-1.75%
23.11.20
23.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Enzon Pharmaceuticals
Start price
Target price
Perf. (%)
€0.10
14.11.20
14.11.20
-
14.11.21
14.11.21
120.00%
14.01.21
14.01.21
Risky Investment
Nicheplayer
Higher risks for its business
Horizon Pharma plc
Start price
Target price
Perf. (%)
€61.15
13.11.20
13.11.20
-
13.11.21
13.11.21
30.20%
15.07.21
15.07.21
Could be very worthwhile Investment >20% year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.60
13.11.20
13.11.20
€52.00
1.38%
14.11.20
14.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.00
09.11.20
09.11.20
€55.00
2.66%
10.11.20
10.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Pfizer Inc.
Start price
Target price
Perf. (%)
€33.30
09.11.20
09.11.20
€37.95
-11.94%
17.12.20
17.12.20
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Bellicum Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.30
07.11.20
07.11.20
-
07.11.21
07.11.21
15.65%
15.07.21
15.07.21
Probably not worthwhile Investment
WAVE Life Sciences Ltd
Start price
Target price
Perf. (%)
€5.80
07.11.20
07.11.20
-
07.11.21
07.11.21
-0.34%
15.07.21
15.07.21
Could be very worthwhile Investment >20% year
Aphria Inc.
Start price
Target price
Perf. (%)
€5.20
07.11.20
07.11.20
€6.40
23.49%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Very Future proof/growth oriented business model
Revenue growth >5% per year expected